<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874209</url>
  </required_header>
  <id_info>
    <org_study_id>2015-15</org_study_id>
    <secondary_id>2015-A00328-41</secondary_id>
    <nct_id>NCT02874209</nct_id>
  </id_info>
  <brief_title>Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the central and
      peripheral motor neurons, characterized by the rapidity of its evolution (median survival of
      3 years). The pathophysiology of the disease is still poorly understood. Neuronal death
      results from several cellular mechanisms entangled, including mitochondrial dysfunction. The
      absence of diagnostic marker causes a significant delay in diagnosis, on average a year. On
      the other hand, the wish biomarker is important for therapeutic trials. Recently, MRI sodium
      (23Na) demonstrated its importance to detect noninvasively sodium accumulations associated
      with neuronal suffering. This neuronal pain can be caused by mitochondrial dysfunction
      causing the accumulation in the sodium and calcium cell causing neuronal death. These studies
      were conducted in multiple sclerosis, Alzheimer's disease, Huntington's disease, stroke and
      brain tumors. They demonstrated that sodium MRI could be an effective and sensitive biomarker
      for detecting and quantifying neuronal degeneration. The goal of this study is to assess
      neuronal damage noninvasively by MRI sodium in amyotrophic lateral sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central conduction time of the potential muscle through transcranial magnetic stimulation</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patient with amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sodium MRI</intervention_name>
    <arm_group_label>Patient with amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_label>Healthy volunteer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amyotrophic lateral sclerosis patient according to the El Escorial criteria revised
             Brooks et al. 2000 bulbar or spinal beginning

        Exclusion Criteria:

          -  patient or healthy volonteer presenting MRI contre indications to this exam.

          -  patient or healthy volonteer presenting severe high blood pressure undergoing
             medication to treat it or not.

          -  patient or healthy volonteer having chronic psychiatric illness, dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielles DESALBRES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aude GRAPPERON, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aude GRAPPERON, MD</last_name>
    <email>aude.grapperon@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Masreille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude Grapperon, MD</last_name>
      <email>aude.grapperon@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

